Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 30c, Revenues Beat; Offers FY20 Revenue Guidance
February 25, 2020 4:17 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $4.42, $0.30 better than the analyst estimate of $4.12. Revenue for the quarter came in at $581.74 million versus the consensus estimate of $561.69 million.
"With more than $2 billion of revenue and double-digit top- and bottom-line growth, we delivered strong 2019 financial results while making significant investments to support the continued robust... More
